Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Heart failure

Androgen deprivation therapy 'increases heart failure risk'

Patients with prostate cancer treated with androgen deprivation therapy were 72% more likely to experience heart failure than those unexposed to the therapy, a study has shown.

Prostate cancer cells


Study finds that androgen deprivation therapy increases the risk of heart failure in patients with prostate cancer but concludes that the benefits may still outweigh the risks

Patients with prostate cancer who are treated with androgen deprivation therapy (ADT) are more likely to develop heart failure than unexposed patients, according to a study in the Journal of Clinical Pharmacology (7 November 2018)[1].

The research used health insurance data from Taiwan on 3,050 patients diagnosed with prostate cancer between 2001 and 2012. The team compared the rates of heart failure in 1,244 patients who received ADT and 1,806 patients who did not, over a one-year period.

During follow-up they found that ADT users were 72% more likely to experience heart failure than non-users (4.00 vs 1.89 incidents per 100 person-years, respectively).

The researchers said that previous research into the association between ADT and heart failure has provided conflicting evidence and had never been explored in East Asian patients. However, they noted that, despite the findings, the benefits of ADT may still outweigh the risks.

“We recommend that clinicians should counsel their patients regarding modifiable heart failure risk factors, suggest they improve their lifestyle, and further provide relevant cardiovascular examination for prostate cancer patients receiving ADT,” the team concluded.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20205887

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Sport and Exercise Medicine for Pharmacists

    Sport and Exercise Medicine for Pharmacists

    All the information you need to provide patients with evidence-based advice on sports and exercise related health matters.

    £27.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Lecture Notes in Pharmacy Practice

    Lecture Notes in Pharmacy Practice

    A comprehensive study guide which summarises the basic principles in pharmacy practice. Clear, bulleted information for quick reference.

    £43.00Buy now
  • MCQs in Pharmacy Practice

    MCQs in Pharmacy Practice

    A study aid with 800 MCQs. Assess your knowledge, analytical skills, and ability to apply this knowledge base in clinical practice.

    £25.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.